Compare BIIB & NTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIIB | NTRS |
|---|---|---|
| Founded | 1978 | 1889 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 24.3B |
| IPO Year | 1991 | N/A |
| Metric | BIIB | NTRS |
|---|---|---|
| Price | $173.17 | $139.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 14 |
| Target Price | ★ $177.40 | $127.77 |
| AVG Volume (30 Days) | ★ 2.7M | 1.1M |
| Earning Date | 10-30-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 2.29% |
| EPS Growth | N/A | ★ 7.22 |
| EPS | ★ 10.97 | 8.58 |
| Revenue | ★ $10,065,900,000.00 | $7,932,900,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | $4.02 |
| P/E Ratio | ★ $15.93 | $16.26 |
| Revenue Growth | ★ 4.77 | 0.96 |
| 52 Week Low | $110.04 | $81.62 |
| 52 Week High | $185.17 | $140.75 |
| Indicator | BIIB | NTRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 66.59 |
| Support Level | $168.56 | $137.60 |
| Resistance Level | $175.94 | $133.80 |
| Average True Range (ATR) | 5.21 | 2.51 |
| MACD | -1.78 | 0.41 |
| Stochastic Oscillator | 34.76 | 84.54 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2024, Northern Trust had assets under custody or administration of $16.8 trillion and assets under management of $1.6 trillion.